The ECFS-CTN cannot guarantee that the information provided here is comprehensive. Please go to the ClinicalTrials.gov link for detailed and up-to-date information on study background, eligibility criteria, study design, outcome measures, study status, participating sites, sponsor contact information and timelines.

You can also contact the CTN coordinating centre for additional information: ECFS-CTN@uzleuven.be (link sends e-mail)

Study Name on
ClinicalTrials.gov (link is external)
Term Safety of Tobramycin Inhalation Powder in Patients With Cystic Fibrosis
Study DrugTobramycin inhalation powder
Type of Study DrugAnti-infective
Study TitleA Single Arm, Open-label, Multicenter, Phase IV Trial to Assess Long Term Safety of Tobramycin Inhalation Powder (TIP) in Patients With Cystic Fibrosis
Study Phase4
Study SponsorNovartis

Link on
clinicaltrials.gov (link is external)

http://clinicaltrials.gov/ct2/show/NCT01519661 (link is external)

Participating ECFS-CTN sitesFrance: Giens, Montpellier, Paris, Reims, Roscoff
Germany: Frankfurt
Italy: Florence, Genoa, Rome, Verona
Spain: Barcelona
Age6 years and older